Skip to main content

and
  1. Article

    Open Access

    Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients

    The role of CHAC1 (cation transport regulator-like protein 1), a recently identified component of the unfolded protein response (UPR) pathway, in gynaecological cancers has not yet been characterised. Now, thi...

    G Goebel, R Berger, A M Strasak, D Egle, E Müller-Holzner in British Journal of Cancer (2012)

  2. Article

    Open Access

    The treatment of early breast cancer in women over the age of 70

    One third of all breast cancers are diagnosed in women aged 70 or over. Older women are a heterogeneous population who are under-represented in clinical trials, and as a result uncertainty can exist as to what...

    A Ring, M Reed, R Leonard, I Kunkler, H Muss, H Wildiers in British Journal of Cancer (2011)

  3. Article

    Open Access

    Idiopathic venous thromboembolic disease is associated with a poorer prognosis from subsequent malignancy

    We carried out a retrospective study of prognosis in Scottish patients diagnosed with cancer within 5 years after a venous thromboembolism (VTE).

    A Jones, D L Stockton, A J Simpson, J T Murchison in British Journal of Cancer (2009)

  4. Article

    Open Access

    Waiting times for systemic cancer therapy in the United Kingdom in 2006

    This audit was conducted to measure waiting times for systemic cancer therapy across the United Kingdom. All patients, aged 16 years or older, commencing their first course of systemic therapy between 13 Novem...

    M V Williams, K J Drinkwater, A Jones, B O'Sullivan, D Tait in British Journal of Cancer (2008)

  5. No Access

    Article

    Patient satisfaction with nurse-led telephone consultation for the follow-up of patients with prostate cancer

    Prostate cancer is being diagnosed earlier and in higher numbers than ever before. The nature of the disease means many patients have to be monitored regularly and for a prolonged period leading to increased p...

    N Shaida, C Jones, N Ravindranath, T Das in Prostate Cancer and Prostatic Diseases (2007)

  6. Article

    Open Access

    Medical student teaching in the UK: how well are newly qualified doctors prepared for their role caring for patients with cancer in hospital?

    A number of studies have identified problems with undergraduate oncology teaching. We have investigated how well prepared newly qualified doctors (first foundation year, or FY1 doctors) are for treating patien...

    J Cave, K Woolf, J Dacre, H W W Potts, A Jones in British Journal of Cancer (2007)

  7. Article

    Open Access

    Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

    The combination of intravenous (i.v.) vinorelbine and epirubicin is highly active in the treatment of metastatic breast cancer (MBC). In an effort to improve patient convenience, we investigated a regimen alte...

    D Serin, M Verrill, A Jones, T Delozier, R Coleman in British Journal of Cancer (2005)

  8. Article

    Open Access

    Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

    Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidenc...

    J J Ord, E Streeter, A Jones, K Le Monnier, D Cranston, J Crew in British Journal of Cancer (2005)

  9. Article

    Open Access

    Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma

    Elevated thymidine phosphorylase has been shown to correlate with increased angiogenesis and poor prognosis in many cancers including transitional cell carcinoma of the bladder. In vitro studies have demonstrated...

    N S Brown, E H Streeter, A Jones, A L Harris, R Bicknell in British Journal of Cancer (2005)

  10. Article

    Open Access

    Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery

    The adequate timing of adjuvant radiotherapy (RT) in breast cancer has become a subject of increasing interest in recent years. A population-based study was undertaken to determine the influence of demographic...

    J Stefoski Mikeljevic, R Haward, C Johnston, A Crellin in British Journal of Cancer (2004)

  11. Article

    Open Access

    Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

    After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of four cycles of adriamycin followed by eight cycles of intravenous CMF, many centr...

    D A Cameron, A Anderson, E Toy, T R J Evans, J H Le Vay in British Journal of Cancer (2002)

  12. Article

    Open Access

    Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion

    As well as being a passive support, the extracellular matrix also regulates key biological processes such as invasion, differentiation and angiogenesis. We have therefore developed an in vitro model of bladder...

    C Fujiyama, A Jones, S Fuggle, R Bicknell, D Cranston in British Journal of Cancer (2001)

  13. Article

    Technical approaches for efficient printing of high-density microarrays and rapid, high-precision fluorescence analysis

    D. Pinkel, G. Hamilton, A. Jones, D. Davy, M. Zorn, R. Segraves in Nature Genetics (1999)

  14. No Access

    Article

    A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor

    ZD1694 ('Tomudex'), a novel, direct and specific thymidylate synthase (TS) inhibitor, was developed in a collaborative research programme between Zeneca Pharmaceuticals and the Institute of Cancer Research (UK...

    I Smith, A Jones, M Spielmann, M Namer, MD Green, J Bonneterre in British Journal of Cancer (1996)

  15. No Access

    Article

    Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients

    The aromatase inhibitor, 'pyridoglutethimide' (PyG), has been shown previously to suppress serum oestrogen levels in postmenopausal breast cancer patients and to achieve clinical responses at a dose of 500 mg ...

    M Dowsett, F MacNeill, A Mehta, C Newton, B Haynes, A Jones in British Journal of Cancer (1991)

  16. No Access

    Article

    The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

    The influence of a new aromatase inhibitor, CGS 16949A on peripheral aromatisation of androstenedione into oestrone was investigated in postmenopausal women with breast cancer. A mixture of 3H androstenedione ...

    PE Lønning, S Jacobs, A Jones, B Haynes, T Powles, M Dowsett in British Journal of Cancer (1991)

  17. No Access

    Article

    Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital

    One hundred and one consecutive patients with newly diagnosed stage I Hodgkin's disease (HD) received treatment at St Bartholomew's Hospital, between 1968 and 1987, with a median follow-up of 12 years. Eleven ...

    TS Ganesan, PFM Wrigley, PA Murray, AG Stansfeld, AJ d'Ardenne in British Journal of Cancer (1990)

  18. No Access

    Article

    Activation of murine 'T' lymphomas in the presence of a human myeloma cell line, RPMI-8226, in vivo

    BC Millar, JL Millar, A Jones, SW Feary, D Robertson, JBG Bell in British Journal of Cancer (1988)

  19. No Access

    Article

    Tumour necrosis factor in man: Clinical and biological observations

    Eighteen patients with advanced cancer have been treated intravenously with human recombinant tumour necrosis factor (rhTNF). The drug produced febrile reactions at all doses although these were preventable by...

    P Selby, S Hobbs, C Viner, E Jackson, A Jones, D Newell in British Journal of Cancer (1987)

  20. No Access

    Article

    Experimental Production of Interstitial Cell Tumours

    A Jones in British Journal of Cancer (1955)